STOCK TITAN

SciSparc Ltd. - $SPRC STOCK NEWS

Welcome to our dedicated page for SciSparc Ltd. news (Ticker: $SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SciSparc Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SciSparc Ltd.'s position in the market.

Rhea-AI Summary
SciSparc Ltd. (SPRC) Announces Pricing of $1.3M Public Offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.83%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) plans to offer its securities in a public offering to raise funds for working capital. The offering is subject to market conditions and the size and terms are uncertain. Aegis Capital Corp. will have the option to purchase additional shares. Interested parties should read the prospectus for more information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.83%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) and Clearmind Medicine Inc. (Nasdaq: CMND) filed a U.S. patent application for using the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia, including in Tourette Syndrome and Parkinson's disease. This collaboration aims to develop novel therapies for movement disorders, emphasizing SciSparc's commitment to pioneering innovative treatments for conditions with unmet need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
none
Rhea-AI Summary
SciSparc Ltd. has received approval from the Israeli Medical Cannabis Agency to conduct a clinical trial for SCI-210 in children with autism spectrum disorder. The company aims to sell SCI-210 first in Israel and then globally. The trial will compare SCI-210 to CBD monotherapy and evaluate safety, tolerability, and efficacy. The trial design includes 60 children and has three primary efficacy endpoints. ASD is a condition that affects social interaction and communication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.95%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Summary
SciSparc announces positive topline results from Phase IIa trial of SCI-110 for Alzheimer's disease and agitation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.94%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
management
SciSparc Ltd.

Nasdaq:SPRC

SPRC Rankings

SPRC Stock Data

2.88M
324.71k
0.02%
2.42%
6.6%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Tel Aviv